- The 28th Annual Meeting of the
Huntington Study Group (Virtual),November 4 - 6, 2021 David Cooper , M.D., vice president of clinical research CNS, will present an overview of the ongoing clinical trials of AMT-130 in Huntington’s Disease, HD-GeneTRX-1 and -2, and participate in a Q&A session onFriday, November 5 th at3:15 p.m. ET .- An encore poster presentation entitled, “Demographics and healthcare resource utilization (HRU) in US patients with Huntington’s Disease: data from the Huntington’s Disease Burden of Illness (HDBOI) study” will also be available to view at the
Poster Pavilion to registered participants.
- Virtual Neuroscience 2021 – 50th Annual Meeting,
November 8 - 11, 2021 - Corlieve academic collaborator, Valeria Crepel, Ph.D., will present an encore presentation “CL002, An AAV9 vector expressing engineered miRNA targeting knockdown of GluK2-containing kainite receptors as a novel gene therapy approach for treating intractable temporal lobe epilepsy” on
Thursday, November 11 th at10:00 a.m. ET , Session P152: Antiepileptic Therapies IV.
- Corlieve academic collaborator, Valeria Crepel, Ph.D., will present an encore presentation “CL002, An AAV9 vector expressing engineered miRNA targeting knockdown of GluK2-containing kainite receptors as a novel gene therapy approach for treating intractable temporal lobe epilepsy” on
- Stifel 2021
Virtual Healthcare Conference ,November 15 - 17, 2021 - Members of uniQure’s management team, including
Matt Kapusta , chief executive officer, will participate in virtual one-on-one investor meetings onWednesday, November 17th . - A fireside chat with
Mr. Kapusta will take place the same day from10:40 to 11:10 a.m. ET . The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.
- Members of uniQure’s management team, including
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with severe genetic diseases of the central nervous system (CNS) and liver, including clinical programs in hemophilia B and
uniQure Contacts:
FOR INVESTORS: | FOR MEDIA: | |
Direct: 339-970-7536 | Direct: 617-306-9137 | Direct: 339-970-7558 |
m.cantor@uniQure.com | c.russo@uniQure.com | t.malone@uniQure.com |
Source: uniQure Inc.
2021 GlobeNewswire, Inc., source